{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.88","upperLimit":"95.43","value":"93.53"},{"groupId":"OG001","lowerLimit":"84.40","upperLimit":"90.37","value":"87.72"}]}],"title":"OS Rate at 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.76","upperLimit":"85.73","value":"82.55"},{"groupId":"OG001","lowerLimit":"71.10","upperLimit":"78.92","value":"75.27"}]}],"title":"OS Rate at 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.90","upperLimit":"77.98","value":"74.20"},{"groupId":"OG001","lowerLimit":"60.91","upperLimit":"69.56","value":"65.43"}]}],"title":"OS Rate at 3 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.24","upperLimit":"71.90","value":"67.79"},{"groupId":"OG001","lowerLimit":"55.72","upperLimit":"64.64","value":"60.34"}]}],"title":"OS Rate at 4 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.80","upperLimit":"69.64","value":"65.42"},{"groupId":"OG001","lowerLimit":"49.71","upperLimit":"58.89","value":"54.43"}]}],"title":"OS Rate at 5 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.0","upperLimit":"64.7","value":"60.0"},{"groupId":"OG001","lowerLimit":"46.5","upperLimit":"55.9","value":"51.3"}]}],"title":"OS Rate at 7 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"475"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death. For those participants who had not died, OS was censored at the recorded last non-missing date of contact for which the participant was known to be alive.Yearly survival rates, e.g. at 3 years, defined as the probability that a participant was alive at 3 years following randomization, were estimated via the Kaplan-Meier method","dispersionType":"95% Confidence Interval","groups":[{"description":"Ipilimumab (10 mg/kg) as a single dose via a 90 minute intravenous (IV) infusion (not as bolus or IV push) during Days 1, 22, 43 and 64 (every 21 days in the Induction Phase) for a total of four separate doses, until disease recurrence, unacceptable toxicity or withdrawal of consent. During the maintenance phase, Ipilimumab was administered at a dose of 10 mg/kg, by IV infusion, every 12 weeks, beginning at Week 24, until disease recurrence, unacceptable toxicity or withdrawal of consent, for a maximum of 3 years (Week 156).","id":"OG000","title":"Ipilimumab 10mg/kg"},{"description":"Placebo as a single dose via a 90 minute intravenous (IV) infusion (not as bolus or IV push) during Days 1, 22, 43 and 64 (Induction Phase) for a total of four separate doses, until disease recurrence, unacceptable toxicity or withdrawal of consent. During the maintenance phase, placebo was administered by IV infusion every 12 weeks, beginning at Week 24, until disease recurrence, unacceptable toxicity or withdrawal of consent, for a maximum of 3 years (Week 156).","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Intent to Treat Population: All randomized participants,analyzed in the arm to which they were allocated by randomization","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death, assessed up to 9 years","title":"Rate of Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}